Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis

Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis

Objective: to analyze the reasons for discontinuation of traditional disease-modifying antirheumatic drugs (tDMARDs), biologic agents (BAs), and tofacitinib (TOFA) in patients with rheumatoid arthritis (RA) in real clinical practice.Patients and methods. The authors carried out a retrospective analy...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu. V. Muraviev, G. I. Gridneva, L. A. Muravieva, N. V. Muravieva, A. V. Alexeeva, K. S. Nurbaeva, K. M. Mikhailov, A. V. Rozov
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2018-12-01
Series:Современная ревматология
Subjects:
rheumatoid arthritis
disease-modifying antirheumatic drugs
biologic agents
adverse reactions
treatment inefficiency
Online Access:https://mrj.ima-press.net/mrj/article/view/869
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items